The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: Five‐year results of a phase I–II study and initial findings of a randomized phase III trial
Abstract
Background and Objectives: The objectives of this study were to test the feasibility of sole interstitial high‐dose‐rate brachytherapy (HDR‐BT) after breast‐conserving surgery (BCS) for T1 breast cancer in a phase I–II study, and to present the initial findings of a phase III trial comparing the efficacy of tumor bed radiotherapy (TBRT) alone with conventional whole breast radiotherapy (WBRT). Methods: Forty‐five prospectively selected patients with T1 breast cancer undergoing BCS were enrolled into a phase I–II study of TBRT alone, using interstitial HDR implants. HDR‐BT of 7 × 4.33 Gy (n = 8) and 7 × 5.2 Gy (n = 37) was delivered to the tumor bed. Based on the results of this phase I–II study, a further 126 patients were randomized to receive 50 Gy WBRT (n = 63) or TBRT alone (n = 63); the latter consisted of either 7 × 5.2 Gy HDR‐BT (n = 46) or 50‐Gy wide‐field electron irradiation (n = 17). Breast cancer related events and side effects were assessed. Results: In the phase I–II study, at a median follow‐up of 57 months, 2 (4.4%) local, 3 (6.7%) axillary, and 3 (6.7%) distant failures were observed. Two patients (4.4%) died of breast cancer. The 5‐year probability of cancer‐specific, relapse‐free and local recurrence‐free survival was 90.0%, 85.9%, and 95.6%, respectively. The cosmetic results were judged to be excellent in 44 of 45 patients (97.8%). Severe (higher than grade 2) skin sequelae or fibrosis was not found. Symptomatic fat necrosis occurred in one patient (2.2%). In the phase III study, at a median follow‐up of 30 months, the locoregional tumor control was 100% in both arms. The 3‐year probability of cancer‐specific and relapse‐free survival was 98.1% and 98.4% in the WBRT group and 100% and 94.4% in the TBRT group, respectively (P = NS). There was no significant difference between the two treatment arms regarding the incidence of radiation side effects. Conclusions: Five‐year results of our phase I–II study prove that sole HDR‐BT of the tumor bed with careful patient selection and adequate quality assurance is a feasible alternative to WBRT. However, long‐term results of phase III trials are required to determine the equivalence of TBRT alone, compared with WBRT in the management of selected patients with early breast cancer. J. Surg. Oncol. 2002;80:121–128. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arriagada, R., Lê, M. G., Rochard, F., & Contesso, G. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1558 · Cited by 612
Cited by
Smith, B. D., Arthur, D. W., Buchholz, T. A., Haffty, B. G., Hahn, C. A., Hardenbergh, P. H., Julian, T. B., Marks, L. B., Todor, D. A., Vicini, F. A., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.031 · Cited by 872
Polgár, C., Limbergen, E. V., Pötter, R., Kovács, G., Polo, A., Lyczek, J., Hildebrandt, G., Niehoff, P., Guinot, J. L., Guedea, F., et al. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.01.014 · Cited by 633
Self-citationPolgár, C., Fodor, J., Major, T., Németh, G., Lövey, K., Orosz, Z., Sulyok, Z., Takácsi-Nagy, Z., & Kásler, M. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.022 · Cited by 346
Self-citationLimited-Field Radiation Therapy in the Management of Early-Stage Breast Cancer
Vicini, F. A., Kestin, L., Chen, P., Benitez, P., Goldstein, N. S., & Martinez, A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg023 · Cited by 280
Metadata
- Authors
- Polgár, C., Sulyok, Z., Fodor, J., Orosz, Z., Major, T., Takácsi‐Nagy, Z., Mangel, L. C., Somogyi, A., Kásler, M., & Németh, G.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2002-06-20
- Volume
- 80
- Issue
- 3
- Pages
- 121-128
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W1993977806
- Cited by
- 229
- References
- 1
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.